Ivan Kairatov stands at the intersection of laboratory innovation and clinical application, bringing years of experience as a biopharma expert focused on the research and development of oncology therapeutics. With deep roots in the study of tumor biology and the integration of high-tech solutions in medicine, he has witnessed firsthand the shift from broad-spectrum treatments to the era of precision medicine. His insights are particularly vital today as primary liver cancer—encompassing hepatocellular carcinoma and intrahepatic cholangiocarcinoma—continues to pose one of the most significant challenges in global health. Through his work, Kairatov helps bridge the gap between complex molecular frameworks and the tangible reality of patient care in the hospital ward.
In this discussion, we explore the evolving landscape of liver cancer through the lens of the “Hallmarks of Cancer” framework, which has recently been adapted specifically for liver tumors. The conversation delves into the biological nuances that separate different forms of liver cancer and the logistical complexities of integrating genomic testing into standard hospital workflows. We also examine the dramatic rise in patient survival rates brought about by immunotherapy and the structural changes required in modern clinics to ensure that molecular discoveries translate into personalized treatment plans for the nearly one million people diagnosed each year.
Primary liver cancer remains a leading cause of global cancer mortality with nearly one million new cases annually. How do the biological differences between hepatocellular carcinoma and intrahepatic cholangiocarcinoma dictate your clinical approach, and what specific steps are taken to identify the most effective treatment path for each?
When we look at the staggering figure of 830,000 deaths annually, it becomes clear that we cannot treat liver cancer as a monolithic disease. Hepatocellular carcinoma, or HCC, is the most common form and is largely driven by sustained growth signaling and the formation of new blood vessels, which makes it a prime candidate for therapies that target the tumor’s blood supply. On the other hand, intrahepatic cholangiocarcinoma, or iCCA, is biologically distinct; it often involves altered metabolism and is significantly more likely to harbor specific genetic mutations. To identify the right path, we start with a high-resolution biopsy and molecular profiling to see which “hallmarks” are most active. This allows us to move away from a guessing game and instead craft a strategy that hits the tumor where it is most vulnerable, whether that is through blocking its nutrient supply or using precision drugs.
Advanced liver cancer treatment has evolved from a median survival of less than one year to over two or three years. What are the practical challenges of implementing modern immunotherapy combinations in a hospital setting, and what metrics do you use to evaluate if a patient is responding to these therapies?
The leap from a survival rate of under 12 months to potentially over three years is nothing short of a revolution, but it brings a heavy logistical burden to the hospital floor. Implementing these immunotherapy combinations requires a highly coordinated team of specialists because these drugs can trigger unique immune-related side effects that look very different from traditional chemotherapy. We are constantly monitoring liver function tests and using advanced imaging to look for signs of tumor shrinkage or “pseudoprogression,” where a tumor might temporarily look larger because it is being swarmed by immune cells. It is a delicate balance of watching the clock and the patient’s vitals, ensuring that the body is fighting the cancer without attacking itself. Seeing a patient who was once facing a terminal few months suddenly regain the energy to go for walks or spend time with family is the ultimate metric of success, beyond just the numbers on a scan.
Approximately 45 percent of bile duct cancers now harbor targetable genetic alterations such as FGFR2 fusions or IDH1 mutations. How should clinics integrate genomic testing into their routine workflow, and what are the trade-offs when choosing between targeted therapies versus traditional systemic treatments?
Integrating genomic testing is no longer a luxury; it is a necessity when nearly half of our iCCA patients have mutations like FGFR2, IDH1, ERBB2, or BRAF that we can actually do something about. The ideal workflow involves getting a tissue sample to the lab for next-generation sequencing the moment a diagnosis is made, so we aren’t wasting precious weeks on treatments that won’t work. The trade-off is often between the broad, hammer-like approach of systemic chemotherapy and the “sniper” approach of targeted therapy, which is usually better tolerated but can eventually lead to drug resistance. We have to weigh the immediate need to stabilize the patient against the long-term goal of hitting a specific molecular target. It is a high-stakes decision-making process where we look at the genetic map of the tumor to decide which weapon will provide the most durable response for that specific individual.
The growth of liver tumors is often driven by distinct processes like immune evasion and new blood vessel formation. Could you explain the step-by-step biological mechanisms that allow these tumors to bypass the immune system and provide an anecdote of how disrupting these processes has changed patient outcomes?
Liver tumors are masters of disguise; they create a microenvironment that essentially puts the immune system to sleep, often by expressing “off-switch” proteins that tell T-cells to ignore the cancer. Simultaneously, they send out signals to build a chaotic web of new blood vessels, ensuring the growing tumor is well-fed while also creating a physical barrier against immune intervention. I remember a case where a patient with a massive HCC tumor had exhausted all standard options, but by using a combination that normalized the blood vessels while simultaneously waking up the immune system, the tumor began to melt away. This “dual-hit” approach essentially stripped the tumor of its cloaking device and its food source at the same time. Watching a patient go from a state of total frailty back to a functional life because we finally understood the “hallmarks” of their specific tumor is what drives this research forward.
Precision oncology aims to bridge the gap between laboratory discoveries and bedside care for patients with limited options. What specific infrastructure is required to turn molecular insights into personalized care, and how do you manage patient expectations when a targetable mutation is not found?
To turn a lab discovery into a bedside treatment, you need a multidisciplinary powerhouse—like the one at Mount Sinai—where hepatologists, surgeons, and molecular biologists sit in the same room to review cases. This requires not just high-tech sequencing machines, but also robust data systems that can interpret complex genetic information into actionable clinical reports in real-time. Managing expectations is perhaps the hardest part of my job; when we tell a patient that their tumor doesn’t have one of the 45 percent of targetable mutations, it can feel like a door is closing. In those moments, we emphasize that “no mutation” doesn’t mean “no treatment,” as it often clarifies that they are better candidates for the latest immunotherapy combinations. We focus on the fact that we are still using data to refine their care, ensuring they aren’t subjected to toxic treatments that their biology isn’t designed to respond to.
What is your forecast for liver cancer?
I believe we are on the cusp of a major turning point where liver cancer will transition from a largely fatal diagnosis to a manageable chronic condition for a significant portion of patients. As we continue to refine the “Hallmarks of Liver Cancer” framework, our ability to pair the right patient with the right drug—whether it’s a targeted inhibitor for an FGFR2 fusion or a novel immunotherapy cocktail—will become almost instantaneous. Within the next decade, I expect that our survival metrics will shift again, moving from two to three years to five years and beyond as we master the art of sequential therapies. The nearly one million cases we see each year represent a call to action, and I forecast that our deepening understanding of tumor biology will finally allow us to stay one step ahead of the disease’s ability to evolve and resist.
